Presentation is loading. Please wait.

Presentation is loading. Please wait.

1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical.

Published byJared Holland Modified over 9 years ago

Similar presentations

Presentation on theme: "1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical."— Presentation transcript:

1 1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical Officer Pediatric and Maternal Health Staff Office of New Drugs Food and Drug Administration

2 2 PAC Meeting February 2005 Conclusions: Orlistat Minimal use in pediatric patients Insufficient events to draw any conclusions Reports of cholelithiasis during trial and post-marketing surveillance (relationship to therapy vs. underlying obesity and rapid weight loss unclear) FDA recommended continued monitoring of AEs, particularly for the risk of cholelithiasis, for this drug in all populations.

3 3 Background Drug Information Drug: Xenical ® (orlistat) Therapeutic Category: lipase inhibitor Sponsor: Roche Original Market Approval: April 23, 1999 Pediatric Exclusivity Granted: September 12, 2003 OTC switch (adults only): February 7, 2007 Mechanism of action: inhibits absorption of dietary fats

4 4 Background Drug Information Orlistat Rx (Xenical) –Indication (> 12 years of age): Obesity management in conjunction with weight loss Body Mass Index (BMI) > 30 mg/m 2 or 27 mg/m 2 with risk factors (hypertension, diabetes, dyslipidemia) –Dosage: 120 mg TID Orlistat OTC (Alli) –Indication: (> 18 years of age) Weight loss in adults when used with reduced calorie and low-fat diet –Dosage: 60 mg TID with meals containing fat

5 5 Outpatient Drug Use Trends: Orlistat Dispensed prescriptions for all age groups have continued to decrease: from ~1.6 million (Oct 2001- Sept 2002) to 547,000 (Oct 2005- Sept 2006). 1 Orlistat is prescribed mainly in adults. 2 Pediatric patients (ages 1-16) account for <1 % of prescriptions annually. 2 1 Verispan, LLC, Vector One® National (VONA) Data extracted 1-12-2007 2 Verispan, Total Patient Tracker, data extracted 1-18-2007

6 6 Cholelithiasis: Orlistat Adverse Events: cholelithiasis/acute cholecystitis (April 1999 through Dec 2006) Domestic cases (all ages): 37 Pediatric cases: one, previously described No additional pediatric cases since Feb 2005 Conclusion: Some concern re: possible association between cholelithiasis and orlistat use in all populations No safety concern specific to pediatrics

7 7 Labeling Change: Orlistat Jan 2007 Precautions: General Substantial weight loss can increase risk of cholelithiasis Clinical trial of type 2 Diabetes prevention: orlistat: 47/1649 (2.9%) placebo: 30/1655 (1.8%) Incidence of cholelithiasis similar at similar amounts of weight loss Postmarketing reports: pancreatitis

8 8 PAC Meeting April 2007 Summary: Orlistat Minimal use in pediatric patients Additional cases of cholelithiasis identified in adults Labeling reflects an increased risk of gallstone formation with substantial weight loss. FDA recommends routine monitoring of AEs for this drug in all populations. AE reporting for nonprescription products will be required in the near future. Does the Advisory Committee concur?

9 9 Acknowledgements OSE Mark Avigan Vicky Borders- Hemphill Solomon Iyasu Rosemary Johann- Liang Joslyn Swann OPT Dianne Murphy Barbara Gould DMEDP Eric Colman Oluchi Elekwachi Theresa Kehoe Bruce Stadel DNCE Bindi Nikhar Joel Schiffenbauer Steven Osborne PMHS Lisa Mathis Jean Temeck Kristin Phucas

Download ppt "1 One Year Post Exclusivity Adverse Event Review Update: Orlistat Pediatric Advisory Committee Meeting April 11, 2007 Hari Cheryl Sachs, MD, FAAP Medical."

Similar presentations

Overview of Overview of Sheryl Murphy, MS, RD Medical Affairs GlaxoSmithKline.

Overview of Overview of Sheryl Murphy, MS, RD Medical Affairs GlaxoSmithKline.
Dermatologic and Ophthalmic Drugs Advisory Committee July 12, 2004 1 Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.

Dermatologic and Ophthalmic Drugs Advisory Committee July 12, Clinical Wrap-Up Denise Cook, M.D. Medical Officer Division of Dermatology and Dental.
OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.

OBESITY and CHD Nathan Wong. OBESITY AHA and NIH have recognized obesity as a major modifiable risk factor for CHD Obesity is a risk factor for development.
12-16-031 Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.
Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.

Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.
Prescription Medications David L. Gee, PhD Professor of Food Science and Nutrition Central Washington University.

Prescription Medications David L. Gee, PhD Professor of Food Science and Nutrition Central Washington University.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
1 Obesity Treatment in Special Populations Smokers –All smokers, regardless of weight, should quit smoking. –Implement weight gain prevention, treatment.

1 Obesity Treatment in Special Populations Smokers –All smokers, regardless of weight, should quit smoking. –Implement weight gain prevention, treatment.
1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.
1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.

1 One Year Post Exclusivity Adverse Event Review as Mandated by the Best Pharmaceuticals for Children Act Presented at the Psychopharmacologic Drugs Advisory.
An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,

An Update on NSAID Labeling and Data Review DSaRM Advisory Committee February 10, 2006 Sharon Hertz, M.D. Deputy Director Division of Anesthesia, Analgesia,
Management of Obesity and Dyslipidemia Presented by : Faisal Hassan Hussain.

Management of Obesity and Dyslipidemia Presented by : Faisal Hassan Hussain.
Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,

Center for Drug Evaluation and Research Patterns of Prescription Weight-Loss Drug Use Endocrinologic and Metabolic Drugs Advisory Committee Meeting Rockville,
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
WHAT IS BMI? BMI BODY MASS INDEX- BASED ON HEIGHT AND WEIGHT TO DETERMINE AMOUNT OF FAT AN INDIVIDUAL HAS OBESE BMI > 30.

WHAT IS BMI? BMI BODY MASS INDEX- BASED ON HEIGHT AND WEIGHT TO DETERMINE AMOUNT OF FAT AN INDIVIDUAL HAS OBESE BMI > 30.
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.

Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.
1 One Year Post Exclusivity Adverse Event Review: Orlistat Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP Medical Officer.

1 One Year Post Exclusivity Adverse Event Review: Orlistat Pediatric Advisory Committee Meeting February 14, 2005 Hari Cheryl Sachs, MD, FAAP Medical Officer.

Similar presentations

Ads by Google